Aptose Biosciences (APTO) Tops Q2 EPS by 8c

Aptose Biosciences (NASDAQ: APTO) reported Q2 EPS of ($0.28), $0.08 better than the analyst estimate of ($0.36).

"During the second quarter we were focused on advancing our Phase 1b clinical trial of APTO-253 for AML and other blood cancers, as we expanded the internal clinical operations capabilities, expanded the scope of preeminent investigators and centers associated with the development of this program, and initiated preclinical collaborations to explore combination treatment strategies with other drug developers. APTO-253 displays a mechanism of action that is well-differentiated and potentially complementary to currently available therapies," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. "We are making progress in building a specialized oncology drug development organization dedicated to translating new understandings in transcriptional regulation and epigenetics into advanced medicines such as APTO-253 for patients with hematological malignancies."

For earnings history and earnings-related data on Aptose Biosciences (APTO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c